US states step in to regulate reprocessors of single-use devices in view of FDA "policy vacuum"
This article was originally published in Clinica
The FDA is facing renewed pressure from industry over its refusal to take regulatory action against the third party processing of single-use devices. The US Medical Device Manufacturers Association (MDMA) said last week that it is contemplating a lawsuit or legislation if the FDA refuses to act on the issue soon.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.